WO2024150146 - ENGINEERED KETOREDUCTASE POLYPEPTIDES
National phase entry:
Publication Number
WO/2024/150146
Publication Date
18.07.2024
International Application No.
PCT/IB2024/050231
International Filing Date
10.01.2024
Title **
[English]
ENGINEERED KETOREDUCTASE POLYPEPTIDES
[French]
POLYPEPTIDES CÉTORÉDUCTASES MODIFIÉS
Applicants **
NOVARTIS AG
Lichtstrasse 35
4056 Basel, CH
Inventors
YE, Ning
Suzhou Novartis Technical Development Co., Ltd.,18-1, Tonglian Road, Bixi Subdistrict
Changshu, Jiangsu 215537, CN
HARDEGGER, Leo Albert
c/o Novartis Pharma AG
Lichtstrasse 35
4056 Basel, CH
HUEBER, Lukas Simon
c/o Novartis Pharma AG
Lichtstrasse 35
4056 Basel, CH
LEEMANS MARTIN, Laura
c/o Novartis Pharma AG
Lichtstrasse 35
4056 Basel, CH
MANN, Gregory
c/o Novartis Pharma AG
Lichtstrasse 35
4056 Basel, CH
PESCHKE, Theo
c/o Novartis Pharma AG
Lichtstrasse 35
4056 Basel, CH
STANGER, Frédéric Valentin
c/o Novartis Pharma AG
Lichtstrasse 35
4056 Basel, CH
ALVIZO, Oscar
c/o CODEXIS, INC.
200 Penobscot Drive
Redwood City, California 94063, US
SUBRAMANIAN, Nandhitha
c/o CODEXIS, INC.
200 Penobscot Drive
Redwood City, California 94063, US
Priority Data
PCT/CN2023/071908
12.01.2023
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 4666 | |
| EPO | Filing, Examination | 69595 | |
| Japan | Filing | 590 | |
| South Korea | Filing | 574 | |
| USA | Filing, Examination | 31810 |
Total: 107235 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present disclosure provides engineered ketoreductase enzymes having improved enzymatic activity including the ability of selectively reducing tert-butyl rel-(3aR,6aS)-5- oxohexahydrocyclopenta[c]pyrrole-2(1H)-carboxylate to tert-butyl rel-(3aR,5s,6aS)-5- hydroxyhexahydrocyclopenta[c]pyrrole-2(1H)-carboxylate. Also provided are polynucleotides encoding the engineered ketoreductase enzymes, host cells capable of expressing the engineered ketoreductase enzymes, and methods of using the engineered ketoreductase enzymes.[French]
La présente invention concerne des enzymes cétoréductases modifiées ayant une activité enzymatique améliorée y compris la capacité de réduire sélectivement le rel-(3aR,6aS)-5-oxohexahydrocyclopenta[c]pyrrole-2(1H)-carboxylate de tert-butyle en rel-(3aR,5s,6aS)-5-hydroxyhexahydrocyclopenta[c]pyrrole -2(1H)-carboxylate de tert-butyle. L'invention concerne également des polynucléotides codant pour les enzymes cétoréductases modifiées, des cellules hôtes capables d'exprimer les enzymes cétoréductases modifiées, et des procédés d'utilisation desdites enzymes cétoréductases modifiées.